Caladrius Biosciences (NASDAQ:CLBS) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.20, Fidelity Earnings reports.
Shares of NASDAQ:CLBS traded down $0.68 during midday trading on Friday, reaching $4.53. The company had a trading volume of 21,628 shares, compared to its average volume of 36,147. The company has a market capitalization of $47.56 million, a P/E ratio of -2.54 and a beta of 1.22. Caladrius Biosciences has a 52-week low of $2.91 and a 52-week high of $11.65.
A number of brokerages recently weighed in on CLBS. Zacks Investment Research raised shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a report on Wednesday, September 12th. Chardan Capital reissued a “buy” rating on shares of Caladrius Biosciences in a report on Wednesday, August 29th. Finally, HC Wainwright boosted their price target on shares of Caladrius Biosciences to $15.00 and gave the stock a “buy” rating in a report on Monday, September 10th.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/10/caladrius-biosciences-clbs-posts-earnings-results-beats-estimates-by-0-20-eps.html.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.
Featured Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.